Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy

Jordan Gauthier • 28 Jan 2021
TCT 2021
General Leukemia Lymphoma

Jordan Gauthier, MD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the relationship between interleukin-15 (IL-15) serum concentrations, anti-tumor efficacy, and in vivo CAR T-cell kinetics in patients treated with anti-CD19 CAR T-cell therapies. IL-15 serum concentrations are associated with higher probabilities of response and higher CAR T-cell in vivo expansion and persistence. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Disclosures

Consulting: JMP, Eusapharma, Multerra Bio

More from Jordan Gauthier

3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
1:46
IACH webinar: continuing the CAR-T discussion amid COVID-19
Jordan Gauthier • 30 Mar 2020
3:50
CLL outcomes after CD19 CAR-T with ibrutinib
Jordan Gauthier • 30 Mar 2020
3:06
Repeat infusions of CD19 CAR-T
Jordan Gauthier • 30 Mar 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals